Ethereum Drops Below This Key Level; XDC Network Emerges As Top Gainer

Bitcoin (CRYPTO: BTC), the most valued cryptocurrency in the world, recorded losses, but traded above the key $17,000 level on Thursday. Ethereum (CRYPTO: ETH), also traded lower, falling below the $1,300 level.

Bitcoin (CRYPTO: BTC), the most valued cryptocurrency in the world, recorded losses, but traded above the key $17,000 level on Thursday.

Ethereum (CRYPTO: ETH), also traded lower, falling below the $1,300 level.

XDC Network (CRYPTO: XDC) was the top gainer over the prior 24 hours, while Neutrino USD (CRYPTO: USDN) turned out to be the biggest loser.

At the time of writing, the global crypto market cap rose to $880.16 billion, recording a 24-hour gained of 0.6%. BTC was trading lower by 2.6% at $17,526, while ETH fell by around 4.3% to $1,275 on Thursday.

Here are the top ten crypto gainers and losers over the past 24 hours:

Gainers

  • XDC Network (CRYPTO: XDC)

Price: $0.02443
24-hour gain: 4.7%

  • Bitcoin SV (CRYPTO: BSV)

Price: $48.11
24-hour gain: 4.3%

  • Aptos (CRYPTO: APT)

Price: $4.75
24-hour gain: 2.7%

  • Chiliz (CRYPTO: CHZ)

Price: $0.1423
24-hour gain: 2.4%

  • ImmutableX (CRYPTO: IMX)

Price: $0.46
24-hour gain: 2.2%

Losers

  • Neutrino USD (CRYPTO: USDN)

Price: $0.6326
24-hour drop: 17.2%

  • Toncoin (CRYPTO: TON)

Price: $2.38
24-hour drop: 7.6%

  • EthereumPoW (CRYPTO: ETHW)

Price: $3.47
24-hour drop: 6.5%

  • Flow (CRYPTO: FLOW)

Price: $0.8936
24-hour drop: 6.3%

  • Litecoin (CRYPTO: LTC)

Price: $73.82
24-hour drop: 6.1%

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Datopotamab Deruxtecan-based Combinations Show Promising Clinical Activity in Patients With Advanced Non-small Cell Lung Cancer

Initial results from the TROPION-Lung02 Phase Ib trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in patients with previously untreated or pretreated, advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

AZN